---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-025445"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2022-09-09T23:59:59+00:00"
generated_at: "2026-06-23T12:10:35.968079+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Anebulo reports Q4 net loss $0.10/share; cash $14.5M; positive Phase 2 data for ANEB-001

## Summary
- Q4 fiscal 2022 net loss of $2.3M ($0.10 per share), vs $29.1M ($1.59) in prior year quarter.
- Operating expenses Q4 $2.3M; fiscal year $6.8M; cash burn Q4 $2.0M; cash at June 30 $14.5M.
- Positive Phase 2 Part A topline: ANEB-001 significantly reduced VAS feeling high (p<0.0001) and improved alertness (p<0.01).
- Plan to initiate Part B evaluating lower doses by end of Q3 2022; IND submission for U.S. trials by end of 2022.
- Inaugural R&D Day scheduled for September 26, 2022 in New York City; Part B data to be presented.

## SEC filing metadata
- accession: 0001493152-22-025445
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2022-09-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315222025445/0001493152-22-025445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315222025445/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-025445
- JSON: https://secwatch.observer/filing/0001493152-22-025445.json
- Plain text: https://secwatch.observer/filing/0001493152-22-025445.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.